| Literature DB >> 16609947 |
Madhvi Rajpurkar1, Patricia Alcasabas, Indulekha Warrier, Rudolph P Valentini, Nancy Fassinger, Daniel A C Frattarelli, Yaddanapudi Ravindranath.
Abstract
All trans retinoic acid (ATRA) combined with chemotherapy has become the mainstay of treatment for patients with acute promyelocytic leukemia (APL). Renal dysfunction (RD) is commonly seen in patients with APL. We describe a patient with APL and multi-organ failure, who was on chronic veno-venous hemofiltration followed by hemodialysis (HD) and later peritoneal dialysis (PD), who received ATRA. ATRA levels were assessed as the body clearance of ATRA in children on HD and/or PD was unknown. Neither HD nor PD significantly affected ATRA levels, suggesting that dose modifications of ATRA may not be necessary for children with these forms of renal replacement therapy. 2007 Wiley-Liss, IncEntities:
Mesh:
Substances:
Year: 2007 PMID: 16609947 DOI: 10.1002/pbc.20844
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167